The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not suitable for ...

AstraZeneca PLC (LSE/STO/Nasdaq ... Medicines Agency (EMA), recommending approval of Enhertu as a monotherapy for certain breast cancer patients in the European Union (EU). The recommendation ...

Enhertu has already been approved in more than 75 countries, including the EU, for patients with HER2-low metastatic breast cancer based on the DESTINY-Breast04 trial results. As an InvestingPro tip ...

AstraZeneca and Daiichi Sankyo ... endocrine therapy in the metastatic setting. Enhertu is already approved for patients with HR+, HER2-low breast cancer after endocrine therapy based on the ...

The European Commission has approved Daiichi Sankyo and AstraZeneca's Enhertu as the first targeted therapy for HER2-low breast cancer, unlocking a large population of patients who could be ...

(Reuters) - The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are ...

(Alliance News) - AstraZeneca PLC on Friday said its breast cancer therapy, Enhertu, which is being developed jointly with Tokyo-based pharmaceutical company Daiichi Sankyo Co Ltd, has been ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2 ... including in 'HER2-ultralow' use, in breast cancer first Stomach cancer has traditionally been a tough nut for researchers ...